80 likes | 91 Views
Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), and End-User (Hospitals, Others, and Research Institutes)
E N D
Monoclonal Antibodies Market Global Analysis and Forecast to 2028 Published Date : May 2022 Email: sales@theinsightpartners.com
Email: sales@theinsightpartners.com Report Studies Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), and End-User (Hospitals, Others, and Research Institutes) The monoclonal antibodies market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028. 2
Email: sales@theinsightpartners.com Monoclonal Antibodies Market Overview The report highlights the key factors driving the market growth and prominent players with their developments in the market Based on indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. The cancer segment is likely to account for a large market share during 2021–2028. By source, the monoclonal antibodies market is segmented into human, humanized, chimeric, and murine. The human segment held a considerable share of the market in 2021 and is likely to continue its dominance in the market during the forecast period. The preventive administration of "palivizumab" human mAB proves effective against severe respiratory diseases that pose a high risk in infants and immunocompromised adults; it is the only mAB product licensed against infectious diseases. 3
Email: sales@theinsightpartners.com Key Segment Market Segment By Type:- By Source (Human, Humanized, Chimeric, and Murine) Production Method (In-Vitro and In-Vivo) Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others) Application (Therapeutic Applications, Diagnostic Applications, and Research Applications) End-User (Hospitals, Others, and Research Institutes) Download Sample Here 4
Email: sales@theinsightpartners.com Monoclonal Antibodies Market Value $50,000 $40,000 $30,000 CAGR of $20,000 11.8% $10,000 (2021 - 2028) $0 20XX 20XX 20XX 20XX 20XX Download Sample 5
Email: sales@theinsightpartners.com Company Profiles Novartis AG Pfizer Inc. GlaxoSmithKline plc Amgen, Inc Daiichi Sankyo Company, Limited F. Hoffmann-La Roche AG AstraZeneca Elli Lily and Company Bayer AG Bristol-Myers Squibb Company Download Sample Here 6
Email: sales@theinsightpartners.com By Geography North America (the US, Canada, and Mexico) Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific) Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa) South & Central America (Brazil, Argentina, and the Rest of South & Central America). 7
THANK YOU! Phone : +1-646-491-9876 E-Mail : sales@theinsightpartners.com